Several preclinical studies have demonstrated cytotoxic activity and MM growth inhibition using CAR NK cells against various targets, including CS1, CD138, BCMA, and NKG2D ligands102. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.